Daniel Swisher has resigned from his position as president and chief executive officer of Sunesis Pharmaceuticals, effective December 31, 2017, to pursue another executive opportunity. Mr. Swisher will serve as strategic advisor to the board through 2018. Dayton Misfeldt, a member of the Board since 2009, will serve as interim chief executive officer, effective January 1, 2018.  The board has also formed a search committee to find a permanent replacement for Mr. Swisher. “We thank Dan for ...